Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong product development, strategic market shifts, and optimistic future guidance. Despite some headwinds, the company anticipates revenue growth driven by new technology and market expansion, with gross margins expected to improve significantly. The transition to a pharmacy model and international direct sales are strategic moves that promise long-term benefits. Analysts' questions reflect confidence in the company's strategy, despite some uncertainties. Given the market cap, the positive sentiment from product launches and strategic transitions is likely to result in a positive stock price movement over the next two weeks.
Key Financial Performance
Worldwide Sales $1 billion in 2025, a 12% year-over-year growth. U.S. sales increased by 10% to $707 million, and international sales grew by 15% to $308 million. Reasons include strong pump shipments, new technology launches, and expanded pharmacy channel access.
Q4 Worldwide Sales $290 million, a 15% year-over-year growth. U.S. Q4 sales increased by 14% to $210 million, driven by 27,000 pump shipments and pharmacy channel growth. International Q4 sales grew by 17% to $80 million, supported by favorable FX and strong pump and supply shipments.
Gross Margin 54% for the full year 2025, a 3 percentage point increase year-over-year. Q4 gross margin reached 58%, the highest ever. Improvements were due to reduced product costs, manufacturing efficiency, and pricing/channel initiatives.
Adjusted EBITDA 11% of sales in Q4 2025, a 10 percentage point improvement year-over-year. Operating margin was 3% of sales in Q4, a 15 percentage point improvement year-over-year. Reasons include controlled operating expenses and reduced stock-based compensation.
Free Cash Flow Positive in Q3 and Q4 2025, contributing to nearly $300 million in total cash and investments by year-end. Reasons include improved profitability and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Control-IQ+: Launched next-generation automated insulin delivery algorithm for type 1 and type 2 diabetes, doubling the addressable market.
FreeStyle Libre 3 Plus and Android Control for Mobi: Launched two new pump features in the U.S., contributing to Q4 growth.
Mobi Tubeless: Preparing for launch in 2026 as the first patch pump with extended wear technology.
SteadiSet and Sigi technology: Pipeline includes extended wear infusion set technology and further miniaturization of Mobi.
Fully closed-loop AID system: Pivotal trial planned for 2026, aiming for FDA filing in 2027.
International expansion: Launched direct commercial operations in the U.K., Switzerland, and Austria, with plans to expand further in 2026 and 2027.
Pharmacy channel: Accelerated efforts to increase pharmacy coverage in the U.S., transitioning to a pay-as-you-go reimbursement model to drive market growth and profitability.
Sales team and processes: Expanded U.S. sales team and updated processes, implementing new systems for efficiencies in 2026.
Gross margin improvement: Achieved record gross margin of 58% in Q4 2025, driven by reduced product costs and manufacturing efficiency.
Pay-as-you-go model: Adopted a new reimbursement structure in the U.S. pharmacy channel to eliminate upfront payments and create predictable revenue streams.
Direct operations in Europe: Transitioned to direct operations in key European markets, improving pricing and margins.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Transition to Pay-as-You-Go (PayGo) Model: The shift to a PayGo reimbursement model in the U.S. pharmacy channel may lead to near-term revenue offsets as upfront payments are eliminated. This transition could also create challenges in scaling pharmacy access and managing the financial impact during the initial phase.
International Direct Operations Transition: The transition to direct commercial operations in countries like Switzerland, U.K., and Austria involves distributor separations and infrastructure setup, which may lead to temporary sales disruptions and additional costs. Similar transitions in other European markets could pose further risks.
Regulatory Approvals and Product Launches: Delays in regulatory approvals for new products, such as the Mobi Tubeless patch pump and other pipeline innovations, could impact the planned product launch timeline and revenue growth.
Economic and Currency Risks: International operations are exposed to foreign exchange fluctuations, which could negatively impact revenue and profitability. Additionally, economic uncertainties in key markets may affect customer purchasing power.
Supply Chain and Manufacturing Efficiency: While efforts to reduce product costs and improve manufacturing efficiency are underway, any disruptions in the supply chain or failure to achieve cost reduction targets could impact gross margins and profitability.
Market Competition: The diabetes care market is highly competitive, and the company faces pressure to maintain its leadership in automated insulin delivery systems. Failure to innovate or respond to competitors' advancements could erode market share.
Customer Transition to Pharmacy Channel: Encouraging existing customers to transition to the pharmacy channel may face resistance, potentially slowing the adoption of the new business model and impacting revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Worldwide sales for 2026 are expected to be in the range of $1.065 billion to $1.085 billion, incorporating $85 million to $95 million in total sales headwinds associated with strategic business model changes. U.S. sales are expected to be in the range of $730 million to $745 million, while international sales are projected to be $335 million to $340 million.
Pump Shipments: Pump shipments in the U.S. are expected to increase 10% to 11% year-over-year in 2026, with renewal pumps comprising more than half of total shipments. Internationally, sales productivity in new direct markets (Switzerland, U.K., Austria) is expected to scale across the year, with additional European markets transitioning to direct sales in Q4.
Gross Margin and Profitability: Gross margin is expected to increase to a range of 56% to 57% in 2026, scaling from nearly 54% in Q1 to 60% in Q4. Adjusted EBITDA is projected to be in the range of 5% to 6% for the full year, with a negative 2% to negative 1% in Q1, returning to positive in Q2.
Pharmacy Channel Transition: The company is transitioning to a pay-as-you-go reimbursement model in the pharmacy channel, expected to drive pump adoption by eliminating upfront payments. Pharmacy sales are anticipated to grow from 4% of U.S. sales in 2025 to 15% in 2026, with long-term expectations of over 70% of sales through this channel.
New Product Launches: Three new product launches are planned for Q2 2026, including the international launch of Mobi, Mobi integration with FreeStyle Libre 3 Plus in the U.S., and Dexcom's 15-day sensor integration globally. The launch of Mobi Tubeless, a patch pump with extended wear technology, is expected in the second half of 2026, pending FDA clearance.
International Expansion: Direct commercial operations in Switzerland, U.K., and Austria began in Q1 2026, with additional European markets transitioning to direct sales in Q4. Direct sales are expected to grow from 5% of international sales in 2025 to 15% in 2026.
Pipeline Developments: The company plans to file a 510(k) submission for Mobi Tubeless in Q2 2026, with a launch in the second half of the year. A pivotal trial for a fully closed-loop algorithm is planned for 2026, supporting an FDA filing in 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you clarify the expected growth in U.S. and OUS shipments for next year, excluding the PayGo changes?
A:John Sheridan stated that overall revenue growth or shipment growth for the year is expected to be in the range of 10% to 11%, indicating double-digit growth in shipments. He also mentioned a return to growth in new shipments.
Q:What is the progress on pharmacy coverage and contracting, and how does it relate to the 20% pump mix expectation for 2026?
A:Leigh Vosseller explained that they have contracts with all major PBMs covering about 80% of lives, but only about 1/3 of lives have formulary access. The pharmacy model is expected to scale up across the year, averaging 20% of pump shipments in 2026. Additionally, about 10% of customers are expected to order supplies through the pharmacy channel on average for the year.
Q:Why is now the right time to transition to the pay-as-you-go model, and what are the long-term pharmacy goals?
A:John Sheridan mentioned that the company has gained experience in the pharmacy business and had discussions with payers, making it the right time for the transition. Leigh Vosseller added that the goal is to build up formulary access and attachment from downstream payer plans, aiming for 70% of sales through the pharmacy channel in 2-3 years. They also believe customers will stick with their technology despite the lack of lock-in periods in the pharmacy model.
Q:Why is the international transition to direct sales a protracted process, and when will it be completed?
A:John Sheridan explained that transitioning to direct sales involves significant operational tasks, such as hiring sales teams and building infrastructure. The process is staged over two years to manage risks, with the majority of the transition expected to be completed by 2027. The company plans to maintain a hybrid model with both direct sales and distributor partnerships.
Q:What are the key levers for margin improvement in 2026 and beyond?
A:Leigh Vosseller highlighted pricing benefits from the pay-as-you-go model, product cost reduction initiatives (e.g., Mobi manufacturing costs being 10%-15% lower than t:slim), and operational efficiencies. New products are designed to have better margin profiles, and the company is focused on reducing headcount needs while improving customer service.
Q:What is driving the expected acceleration in new pump shipments in 2026?
A:John Sheridan attributed the acceleration to new technology (e.g., Mobi with multiple sensor integration and Tubeless implementation), sales force productivity improvements, and the impact of the pharmacy channel. He also mentioned expanding Mobi and FreeStyle Libre 3 into OUS markets.
Q:What is the timeline for the Tubeless Mobi 510(k) submission and approval?
A:John Sheridan confirmed that the 510(k) submission for Tubeless Mobi is planned for the second quarter of the year, with expected approval in the second half of the year.
Q:How will the pharmacy shift impact the P&L and sales growth in 2027 and 2028?
A:Leigh Vosseller explained that the pharmacy shift will create revenue tailwinds as the base of pay-as-you-go customers grows. The transition of existing DME customers to the pharmacy channel will also provide immediate benefits. While 2026 will see headwinds, the model is expected to drive revenue and margin growth in subsequent years.
Q:What is the expected cadence of the $70-$80 million revenue headwind from the PayGo transition in 2026?
A:Leigh Vosseller stated that the headwind will be more pronounced in the latter half of the year, with low single-digit percentages in Q1 scaling up to an average of 20% for the year. Margins are expected to start at 54% in Q1 and reach 60% by Q4.
Q:What is the underlying growth in the international market, considering the transition to direct sales?
A:Leigh Vosseller noted that international markets are strong, with most shipments coming from new customers. The transition to direct sales is expected to provide a mid- to high-single-digit price increase in 2026, despite a $15 million headwind from the transition.
Q:What is driving the confidence in accelerating sales growth in 2027 and beyond?
A:John Sheridan cited the ongoing implementation of the pay-as-you-go model, the opportunity to transition existing customers to the pharmacy channel, and a strong product pipeline, including the first extended wear patch and a fully closed-loop system expected by 2027 or 2028.
Q:What is the expected pricing for the pharmacy channel, and how does it compare to DME?
A:Leigh Vosseller suggested starting with an average of $350 per month per customer for modeling purposes, which is a significant improvement over DME pricing. The pricing will be consistent for both new and existing customers transitioning to the pharmacy channel.
Q:What is the progress in the type 2 diabetes market, and how does the new ADA guideline on C-peptide testing impact CMS discussions?
A:John Sheridan mentioned that the type 2 market doubles their addressable market. The company is focusing on marketing and research for PCP and OUS markets. The new ADA guideline on C-peptide testing could positively influence CMS's review of the NCD, potentially improving Medicare access by August 2026.
Q:How does the pharmacy model reduce reliance on renewal pump shipments?
A:Leigh Vosseller explained that the pharmacy model eliminates the need for 4-year renewal cycles, as customers can continue ordering supplies without purchasing a new pump. This reduces reliance on renewal shipments as a growth driver.
Q:What is the expected gross margin trajectory for 2026?
A:Leigh Vosseller stated that gross margins are expected to expand by 2-3 points in 2026, starting at 54% in Q1 and reaching 60% by Q4. The pharmacy shift and international direct sales transition will contribute to margin expansion.
Q:What is the breakeven timeline for the PayGo model, and what is the free cash flow outlook for 2026?
A:Leigh Vosseller mentioned that the PayGo model breaks even within a few months when considering both new and existing customers. The company expects to be free cash flow neutral in 2026, with a positive trajectory by year-end.
Q:What are the barriers to moving customers from DME to the pharmacy channel?
A:Leigh Vosseller noted that barriers include educating customers on financial benefits, reassuring them about customer service, and obtaining new prescriptions from physicians. These challenges are manageable but require time to address.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact timeline for completing the international transition to direct sales and the precise financial impact of the pharmacy shift on the P&L in 2027 and 2028. Additionally, they did not clarify the exact pricing structure for the pharmacy channel beyond suggesting a starting point for modeling purposes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASP
Austria
Executive VP
FreeStyle Libre
PayGo
Pharmacy
Sales
Switzerland
Tandem milestone
Tubeless
UK
accessibility
base supply
channel experience
channel sale
cycle
destocking inventory
distributor destocking
focus
generation
indicator
infusion
innovation
inventory buyback
lever
model change
model pharmacy
momentum
onboarding
pay
percent base
percentage point
purchase
sale pharmacy
sale pump
sale transition
shipment pharmacy
shipment sale
supply pharmacy
term sale
type diabetes
visibility
TNDM Transcript
Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call highlights strong product development, strategic market shifts, and optimistic future guidance. Despite some headwinds, the company anticipates revenue growth driven by new technology and market expansion, with gross margins expected to improve significantly. The transition to a pharmacy model and international direct sales are strategic moves that promise long-term benefits. Analysts' questions reflect confidence in the company's strategy, despite some uncertainties. Given the market cap, the positive sentiment from product launches and strategic transitions is likely to result in a positive stock price movement over the next two weeks.
Tandem Diabetes Care, Inc. (TNDM) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call indicates positive sentiment with strong product development and strategic plans, including new product launches like Mobi Tubeless and Sigi. Despite some uncertainties in pricing and detailed guidance, the company demonstrates a clear path to growth with international expansion, pharmacy channel leverage, and type 2 diabetes initiatives. The anticipated gross margin improvements and focus on double-digit growth further support a positive outlook. While management avoided some specifics, the overall tone and strategic direction suggest a likely stock price increase in the near term.
Tandem Diabetes Care, Inc. (TNDM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-10
Tandem Diabetes Care, Inc. (TNDM) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call presents a positive outlook with strong sales growth, promising product launches, and strategic market expansion plans. Despite some reduction in U.S. guidance due to competition, the company shows optimism in long-term growth, particularly in international markets and pharmacy channels. The Q&A section highlights management's confidence in achieving significant margin improvements and leveraging new technologies. Given the market cap of approximately $2.6 billion, the stock is likely to react positively within the 2% to 8% range in the short term.
TNDM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
